India’s Patent Office has issued the first-ever compulsory license to a generic drug manufacturer, effectively ending the German pharmaceutical company Bayer’s monopoly in India on the drug sorafenib tosylate, used to treat kidney and liver cancer.
In a groundbreaking case, India’s Patent Office acted on the basis that not only had Bayer failed to price …